Off-Label Use OK When Not Promoted, GSK Exec Says

Law360, New York (May 4, 2011, 7:46 PM EDT) -- Prescribing Wellbutrin for off-label uses is fine, GlaxoSmithKline PLC just can't promote the antidepressant for such uses, a company executive testified Wednesday in the Maryland trial of a former GSK attorney who allegedly obstructed a probe into the drug's marketing.

“Off-label uses, especially in the depression area, aren’t uncommon,” James Millar, GSK vice president of strategic pricing, contracting and marketing, told a jury in the trial of the drugmaker's ex-associate general counsel, Lauren Stevens.

“That’s where clinical judgment comes into play. While you may use Wellbutrin...
To view the full article, register now.